Patent issued for ANAVEX2-73 in anxiety, insomnia
Click Here to Manage Email Alerts
Key takeaways:
- A new patent covers Alzheimer’s drug candidate ANAVEX2-73, as well as ANAVEX-141 and ANAVEX19-144, for insomnia, anxiety or agitation.
- The patent is expected to last until at least 2037.
The U.S. Patent and Trademark Office has issued a patent expanding existing protections for ANAVEX2-73, a drug potentially effective in Alzheimer’s disease, according to a press release from the manufacturer.
U.S. Patent No. 11,813,242 expands Anavex Life Sciences Corp.’s existing patent coverage to include its leading drug candidate, ANAVEX2-73, as well as ANAVEX1-41 and ANAVEX19-144, for the treatment of insomnia, anxiety or agitation.
Image: Adobe Stock
Christopher U. Missling, PhD, CEO and president of Anavex, said in the release the patent is an “important milestone” for protecting the drugs’ commercial potential and demonstrates the company’s “strong overall commitment to protecting the innovation and commercial opportunity of our entire product portfolio.”
The company described ANAVEX2-73 as a drug candidate that targets sigma-1 and muscarinic receptors with the possibility of restoring cellular homeostasis. The drug showed potential to halt or reverse Alzheimer’s disease in preclinical trials and successfully completed other studies in Parkinson’s disease dementia and Rett syndrome, according to the release.
The patent is expected to be in force until at least July 2037. Along with another patent in force until at least 2038, it provides “extensive coverage” of ANAVEX2-73 for treatment of insomnia or anxiety, alone or in combination with ANAVEX19-144 or ANAVEX1-41. The patents also cover a range of dosage forms.